Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Core Insights - Artelo Biosciences, Inc. has published a peer-reviewed article on the role of Fatty Acid Binding Protein 3 (FABP3) in cancer, highlighting its significance in cancer progression and potential as a therapeutic target [1][2][3] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions, including cancer, pain, and neurological disorders [1][4] - The company is advancing a portfolio of selective, dual, and pan inhibitors targeting FABP3, FABP5, and FABP7, positioning itself to explore multiple therapeutic opportunities across oncology and other indications [3][4] Research Findings - The publication emphasizes that FABP3, like FABP5 and FABP7, plays a significant role in cancer progression through mechanisms related to lipid metabolism, hypoxia, and ferroptosis, which are critical for cancer cell survival [2][3] - Genetic and pharmacological inhibition of FABP3 has shown therapeutic benefits in preclinical cancer models, indicating its potential as a target for cancer treatment [2][3] Strategic Direction - The company is committed to advancing innovative therapeutics to address unmet medical needs, with a focus on its lead program, ART26.12, targeting FABP5 for pain treatment while also exploring broader applications of its FABP inhibitor portfolio in various cancers and diseases [4]